<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-129481</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure</dc:title>
<dc:description xml:lang="en">OBJECTIVES: Primary CPCs are those detected in the blood of prostate cancer patients before radical treatment; secondary CPCs are those detected afterwards. Although primary CPCs are frequently found, it has been suggested that only a few will survive and go on to form metastasis. We evaluate the frequency of primary and secondary CPC detection and the association with biochemical failure, relation with clinical-pathological parameters and clinical implications in men treated by radical prostatectomy (RP) for prostate cancer. METHODS: Serial blood samples were taken before surgery and during follow up after RP. Mononuclear cells were obtained by differential gel centrifugation, and CPCs were identified using standard immunocytochemistry using anti-PSA monoclonal antibodies. Age, pathological stage (organ confined, non organ confined), pathological grade, margin status (positive, negative), extracapsular extension, perineural, vascular, and lymphatic infiltration (positive, negative) were compared with the presence/absence of CPCs in patients with and without biochemical failure. Kaplan Meier method was used to compare the unadjusted biochemical failure free survival of patients with and without CPCs. RESULTS: 138 of 423 (32.6%) men undergoing prostate biopsy for an elevated serum PSA were diagnosed of prostate cancer. Of these men 15 (10.9%) were CPC negative. 95 CPC positive men underwent RP. There was no relation between primary CPC detection and clinical-pathological parameters; however, secondary CPCs were associated both with clinical-pathological parameters and biochemical failure. CONCLUSIONS: Primary CPCs are frequently detected in men with prostate cancer, but they are not associated with biochemical failure, so that they may be useful for prostate cancer detection but not for prognosis. The persistence of CPCs after surgery is associated with increased biochemical failure (AU)</dc:description>
<dc:creator>Murray, Nigel P</dc:creator>
<dc:creator>Dueñas, Ricardo</dc:creator>
<dc:creator>Orellana, Nelson</dc:creator>
<dc:creator>Reyes, Eduardo</dc:creator>
<dc:creator>Fuentealba, Cynthia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVO: Las células prostáticas circulantes en sangre (CPCs) primarias son aquellas células prostáticas detectadas en pacientes con cáncer de próstata antes del tratamiento quirúrgico radical, por el contrario, las CPCs secundarias son aquellas detectadas posterior a este tratamiento. Pese a que las CPCs primarias son encontradas frecuentemente en pacientes con cáncer de próstata, solo unas pocas sobreviven y formarán metástasis. Evaluamos la asociación de las CPCs primarias y secundarias con la recidiva bioquímica en hombres con cáncer de próstata tratados con prostatectomía radical. MÉTODOS: Se tomaron muestras de sangre seriadas antes y después del tratamiento quirúrgico, se obtuvieron células mononucleares por centrifugación diferencial y se identificaron las CPCs utilizando inmunocitoquímica. Los datos de edad, estadio patológico, grado patológico, márgenes quirúrgicos, extensión extracapsular, perineural, vascular e infiltración linfática fueron comparados con la presencia o ausencia de CPCs en pacientes con o sin recidiva bioquímica. Se utilizo el método de Kaplan Meyer para comparar la sobrevida libre de enfermedad de los pacientes con o sin CPCs. RESULTADOS: 138 de 423 (32,6%) de los hombres que fueron sometidos a una biopsia prostática por un PSA elevado tuvieron cáncer de próstata, de estos hombres, 15 (10,9%) fueron negativos para CPCs. De los hombres positivos, 95 fueron sometidos a una prostatectomía radical, no existió relación entre la detección de CPCs primarias y los parámetros clínico - patológicos del cáncer, sin embargo, los pacientes con CPCs secundarias se asociaron con mayor tasa de recidiva bioquímica. CONCLUSIONES: Las CPCs primarias son frecuentemente detectadas en hombres con cáncer de próstata, pero no se asocian con recidiva bioquímica, por lo tanto pueden ser útiles para la detección de cáncer de próstata pero no para su pronóstico. La detección de CPCs posterior a la cirugía se asocia con mayores posibilidades de recidiva bioquímica (AU)</dc:description>
<dc:source>Arch Esp Urol;67(8): 684-691, oct. 2014. ilus, graf, tab</dc:source>
<dc:identifier>ibc-129481</dc:identifier>
<dc:title xml:lang="es">La eliminación de células prostáticas circulantes primarias en sangre posterior a la prostatectomía radical disminuye el riesgo de recidiva bioquímica</dc:title>
<dc:subject>^d22921^s22045</dc:subject>
<dc:subject>^d52438</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22921^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22931^s29165</dc:subject>
<dc:subject>^d11914^s22062</dc:subject>
<dc:subject>^d11910^s22040</dc:subject>
<dc:subject>^d11911^s22045</dc:subject>
<dc:subject>^d11910^s22010</dc:subject>
<dc:subject>^d11911^s22066</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:subject>^d9557^s22054</dc:subject>
<dc:subject>^d9553^s29165</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:subject>^d9557^s29165</dc:subject>
<dc:type>article</dc:type>
<dc:date>201410</dc:date>
</metadata>
</record>
</ibecs-document>
